Skip to Content
Merck
All Photos(1)

Key Documents

P5248

Sigma-Aldrich

Etidronate disodium hydrate

≥97% (NMR), solid

Synonym(s):

Dihydrogen (1-hydroxyethylidene)bisphosphonate disodium hydrate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C2H6Na2O7P2 · xH2O
CAS Number:
Molecular Weight:
249.99 (anhydrous basis)
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥97% (NMR)

form

solid

color

white

mp

>300 °C

solubility

H2O: ≥10 mg/mL

storage temp.

2-8°C

SMILES string

[Na+].[Na+].CC(O)(P(O)([O-])=O)P(O)([O-])=O

InChI

1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2

InChI key

GWBBVOVXJZATQQ-UHFFFAOYSA-L

Application

Etidronate disodium hydrate has been used in the synthesis of bisphosphonate derivatives of adenosine triphosphate (ATP)by T4 RNA ligase. It has also been sued to inhibit human farnesyl diphosphate synthase (FDPS).

Biochem/physiol Actions

Etidronate helps to guard chronic ocular hypertension prompted retinal oxidative stress. It stimulates the development of retinal ganglion cells through insulin-like growth factor 1 (IGF-1) signaling pathway. It may possess neuroprotective effects in in vivo and in vitro rat model of glaucoma. Etidronate belongs to bisphosphonates.
Bisphosphonate antiresorptive agent. Less potent inhibitor of farnesyl diphosphate synthase (IC50 = 80 μM) as compared to the nitrogen containing bisphosphonates

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase
Sillero M A G, et al.
Febs Letters, 580(24), 5723-5727 (2006)
Etidronate protects chronic ocular hypertension induced retinal oxidative stress and promotes retinal ganglion cells growth through IGF-1 signaling pathway
Su J and Huang M
European Journal of Pharmacology, 841, 75-81 (2018)
Isoprenoids increase bovine endometrial stromal cell tolerance to the cholesterol-dependent cytolysin from Trueperella pyogenes
Griffin S, et al.
Biology of Reproduction (2018)
M R McClung et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(1), 301-310 (2012-10-20)
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy
Siyoung Kim et al.
European journal of pharmacology, 699(1-3), 14-22 (2012-12-04)
Nitrogen-containing bisphosphonates (NBPs) have greater anti-bone-resorptive effects than non-nitrogen-containing bisphosphonates (non-NBPs). Hence, NBPs are the current first-choice drug for osteoporosis. However, NBPs carry a risk of osteonecrosis of jaws. Some animal and human studies suggest that non-NBPs may have anti-bone-resorptive

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service